Public Health Trace

Get Alerts

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters

Drug Recall Ongoing Historical recordClass II

Phentolamine 20 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Phenobarbital 62. 5mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Pentosan 250 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Pento-Gluc 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Papaverine 40 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Oxytocin 20 units/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Neomycin / Polymyxin / Dexamethasone Ophthalmic Drops, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Naproxen 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Miconazole 3% Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Metoclopramide 5 mg/ml Injection,compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Methylprednisolone Acetate 80 mg/ml Injection, compounded by Olympia, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Methylcobalamin 25 mg/ml Inj and 5000 mcg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Methylcobalamin P 10/ml Creatine 40 mg/ml / Arginine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Metabolase Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Metabolase Forte Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Medroxyprogesterone 150 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Medetomidine 2 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Lipotoxin Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

L-ArGiNINE 200 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Drug Recall Ongoing Historical recordClass II

Ketamine 100 mg/ml Injection, compounded by Olympia Pharmacy, Orlando, FL

by Lowlite Investments, Inc. D/B/A Olympia Pharmacy

Reason: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Recall initiated: May 29, 2013
Reported by FDA: July 17, 2013
Distribution: Nationwide and PR

View recall →

Data last updated: October 3, 2026 ET

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.